Nathan Pennell, MD, PhD of Cleveland Clinic discusses common questions that colleagues ask him regarding pembrolizumab, which is if there is a biomarker that can let clinicians know which patients will respond to the drug. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Is There a Biomarker That Can Help Decide Which Patients Benefit From the Drug?
